This move supports the company’s focus on disciplined execution, scalable operations, and consistent customer delivery. Avid Bioservices is a contract development and manufacturing organization providing process development and CGMP manufacturing services for biopharmaceutical products. In his new role, McAvoy will help guide the company’s growth strategy, with responsibility spanning execution discipline, operational scale, and client engagement.
“As Avid enters its next chapter of growth, we are focused on scaling the organization in a way that strengthens execution and elevates the client experience,” said Kenneth Bilenberg, Chief Executive Officer of Avid Bioservices. “Rich is a thoughtful, highly capable leader with a strong reputation for building disciplined organizations that support reliable delivery. His ability to connect strategy to execution – while maintaining rigor in prioritization, compliance, and risk management – makes him an exceptional fit for Avid. We are excited to welcome Rich to the team as we expand our partnerships and continue raising the bar on what it means to be the easiest CDMO to work with.”
McAvoy brings broad, business-focused leadership experience across strategic investment management, operational finance, accounting, legal, compliance, and risk management. His appointment comes as the biopharmaceutical industry reassesses supply chain strategies amid geopolitical uncertainty, potential trade barriers, and a growing emphasis on U.S.-based manufacturing.
“Avid has built a strong reputation for quality and delivery, and I’m excited to join the team at a time when the company has clear growth ambitions,” said Rich McAvoy, Chief Business Officer of Avid Bioservices. “My focus will be on disciplined execution —ensuring we continue delivering consistently and on time, while supporting an exceptional experience for our customers. Consistent delivery and execution will set us apart from our competitors and make us a preferred partner.”
McAvoy’s addition further strengthens Avid’s leadership team as the company expands its capabilities and deepens partnerships with biopharmaceutical innovators. Avid remains focused on helping customers advance critical programs through reliable execution, responsive collaboration, and high-quality CGMP manufacturing across clinical and commercial supply.
Also read: Viksit Workforce for a Viksit Bharat
Do Follow: The Mainstream formerly known as CIO News LinkedIn Account | The Mainstream formerly known as CIO News Facebook | The Mainstream formerly known as CIO News Youtube | The Mainstream formerly known as CIO News Twitter
About us:
The Mainstream is a premier platform delivering the latest updates and informed perspectives across the technology business and cyber landscape. Built on research-driven, thought leadership and original intellectual property, The Mainstream also curates summits & conferences that convene decision makers to explore how technology reshapes industries and leadership. With a growing presence in India and globally across the Middle East, Africa, ASEAN, the USA, the UK and Australia, The Mainstream carries a vision to bring the latest happenings and insights to 8.2 billion people and to place technology at the centre of conversation for leaders navigating the future.
